Previous 10 | Next 10 |
2023-12-14 11:20:18 ET Summary A PDUFA date of September 18th, 2024 has been set by the FDA to review whether or not the tradipitant should be approved for gastroparesis. The global gastroparesis treatment market is projected to reach $7.19 billion by 2029. An sNDA for the rev...
Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases. Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline. Teva to obtain exclusive worl...
2023-12-08 01:49:54 ET Summary I am upgrading Teva Pharmaceutical to "Buy" for 2024, buoyed by opioid litigation resolution and promising drugs like TEV’574. Strong Q3 2023 performance, marked by revenue growth in Austedo, Ajovy, and Uzedy, and increased R&D investment....
2023-12-06 13:03:09 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Teva: Deeply Undervalued FCF Machine Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings...
2023-12-06 07:11:27 ET More on Pfizer Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024 Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks Seagen gains amid option...
AJOVY ® (fremanezumab) efficacy and safety demonstrated in migraine patients with obesity in post hoc analysis of HALO-LTS 1 and FOCUS 2 phase 3 studies Obesity is a known risk factor for migraine and is frequently associated with an increase in migraine frequency, severi...
2023-12-04 07:12:14 ET More on J&J Stocks To Watch: Big Week On Tap For McDonald's, Shopify, GameStop, And Johnson & Johnson Johnson & Johnson: Sleep Well At Night With The Only AAA-Rated Dividend Aristocrat Johnson & Johnson, Ben Graham, And Defensiv...
2023-12-01 13:40:47 ET More on Amarin, Amneal, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation Amarin Corporation plc (AMRN) Q3 2023 Earnings Call Transcript ...
Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinic...
2023-11-28 23:26:48 ET Summary Abrams' 13F portfolio value decreased from $3.48B to $3.03B this quarter, with the number of holdings decreasing from 16 to 14. The top three stakes make up approximately 49% of the portfolio, while the top five holdings account for around 67%. T...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...